Sequence analysis revealed a PPARγ response element within the chemerin (RARRES2) promoter (Muruganandan et al. 2011); thus, insulin-sensitising drugs that activate PPARγ might be beneficial for the treatment of obesity and T2DM. The gene discussed is RARRES2; the disease is obesity due to melanocortin 4 receptor deficiency.